SEARCH · PubMed Health

Results for “Injections, Intramuscular”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 235 records · Page 13Linked to original sources

PubMed1980

Quadriceps myofibrosis. A complication of intramuscular injections.

Cases of fibrofatty replacement of the quadriceps muscles following repeated intramuscular injections into the thighs of infants and young children are being reported with increasing frequency. In such cases, the knee shows progressive painless limitation of flexion, habitual dislocation of the patella, or both. The recommended treatment is surgical release, done early before secondary adaptive changes occur in the soft tissues, cartilage, and bones comprising the joint. Full flexion should be obtained at the time of surgery. In children, the lag in extension that follows extensive release will usually disappear spontaneously.

Child, Preschool↗

PubMed2003

Distribution and effects of a single intramuscular injection of India ink in mice.

Our goal has been to study the distribution and effects following a single intramuscular injection of a substance using India ink as a tracer. We injected 30 microl India ink in the gastrocnemius muscle group of C57Bl10 mice. Hematoxylin-Eosin, Trichrome stains and polyclonal anti-laminin, anti-collagen-IV and anti-dystrophin were used. The liquid spreads in all directions mainly following the perimysial and epimysial septae. The collagen bundles act as physical barriers preventing passage of the ink particles. In the area of the injection site, necrosis of the fibres is associated with disruption of the basement membrane. In the zones adjacent and distal to the injection site, the liquid progresses by pushing the muscle fibres apart with preservation of the basement membrane. Research based on intramuscular injection of substances should take the following into consideration: a) anatomy of the muscle group injected, b) routes of distribution of the substance, c) types of lesions produced with relation to the site of injection of the liquid, and d) size of the particles of the injected substance.

Animals↗

PubMed1977

Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.

A sensitive radioimmunoassay measuring serum medroxyprogesterone acetate (MPA) has been developed in order to measure and correlate serum MPA concentrations and ovarian function in women following im administration of deop-MPA (DMPA), employing goat anti-MPA-3-(O-carboxymethyl) oxime-bovine serum albumin and MPA-3-(O-carboxymethyl) imino-125I-iodohistamine. In the 3 women studied, im injection of 150 mg of DMPA yielded brief initial serum MPA concentrations ranging from 1.5 to 3 ng/ml for a few days. Serum MPA concentrations gradually declined and remained relatively constant at about 1 ng/ml for 2 to 3 months, declined gradually thereafter reaching 0.2 ng/ml during the 6th month and became undetectable (less than 0.02 ng/ml) about 7-1/2 to 9 months following administration. Serum estradiol remained at early to midfollicular phase levels for 4 to 6 months after DMPA injection and rose to preovulatory levels when serum MPA levels fell below 0.5 to 0.25 ng/ml. Ovulation, however, as evidenced by serum progesterone concentrations did not occur, apparently due to suppression of the LH peak by positive feedback inhibition. Prolonged inhibition of cyclic ovarian function following DMPA injection is caused by slow MPA absorption and persists until serum MPA levels have decreased below 0.1 ng/ml or become undetectable about 7 to 9 months after DMPA administration.

Adult↗

PubMed2002

Transient erectile dysfunction associated with intramuscular injection of botulinum toxin type A.

Autonomic nervous system dysfunction occurs rarely after botulinum toxin type A (BTX-A) intramuscular injections. We report a case of a 23-year-old man with spastic diplegia who had transient erectile dysfunction after intramuscular injection of BTX-A (total dosage, 300 IU, body weight 95 kg) in both hamstring muscles. Some investigators believe that the local spread of the toxin is responsible for autonomic dysfunction, while others believe that the transportation of the toxin to the spinal cord via retrograde flow or via the blood flow after entering the circulation are possible mechanisms of neurologic side effects. On the basis of our case, a retrograde axoplasmic flow to the spinal cord could probably occur because the spinal cord level of hamstring muscles is close to spinal cord levels responsible for erection control.

Adult↗

PubMed1996

Antagonism of xylazine in white-tailed deer with intramuscular injection of yohimbine.

Eighteen free-ranging white-tailed deer (Odocoileus virginianus) were captured near Chestertown, Maryland (USA) from 15 February to 21 March, and 7 October to 13 November 1986. Deer were immobilized by intramuscular injection of 1.1 to 2.2 mg/kg xylazine hydrochloride and 1.8 to 4.4 mg/kg ketamine hydrochloride. Four captive deer from The Pennsylvania State University, Pennsylvania (USA), were immobilized on 16 September 1986 with 1.5 to 2.0 mg/kg xylazine hydrochloride. Intramuscular injection of yohimbine hydrochloride (0.4 mg/kg) was used to antagonize the immobilizations. Free-ranging adult ( > or = 17 months) males could stand after a mean (+/-SE) time of 7.3 +/- 2.4 min, adult females after 8.6 +/- 1.7 min, male fawns after 5.7 +/- 3.3 min, and female fawns after 8.9 +/- 1.9 min. Captive adult males could stand after 20.2 +/- 3.4 min. Intramuscular injections of yohimbine hydrochloride effectively and safely antagonized the xylazine hydrochloride in immobilized deer and were easier to administer than intravenous injections.

Animals↗

PubMedDate not supplied

Using the ventrogluteal site for intramuscular injections.

Traditionally, the dorsogluteal site has been the site preferred by nurses for the administration of medication via intramuscular injection. However, there is evidence to support the use of the ventrogluteal site. It was recently advocated as the site of choice in a respected nursing manual. This article discusses the use of the ventrogluteal site, the intramuscular injection technique, and issues associated with teaching it.

Adult↗

PubMedDate not supplied

Heisenberg in the ER: observation appears to reduce involuntary intramuscular injections in a psychiatric emergency service.

INTRODUCTION: Chemical restraint is controversial. Appropriate use is ill-defined and chemical restraint may be overutilized. During the period of an unrelated observational study for patients with acute psychomotor agitation in a psychiatric emergency service, we noticed a significant reduction in the number of involuntary intramuscular injections administered. RESULTS: We observed a 27% decrease (P=.015) in the number of involuntary intramuscular injections in the 3-month observational study period, compared to 3-month periods before and after the study. CONCLUSION: We suggest that the observation process itself may have been beneficial and may have reduced the incidence of unnecessary intramuscular injections.

Acute Disease↗

PubMed1984

Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.

The pharmacokinetics of ceftriaxone were evaluated in eight adults after doses of 1 g administered by intravenous infusion and 1 and 0.5 g administered by intramuscular injection. Mean peak plasma concentrations were 168 micrograms/ml for 1 g given intravenously, 81 micrograms/ml for 1 g given intramuscularly, and 46 micrograms/ml for 0.5 g intramuscularly. Plasma concentrations were similar by both high pressure liquid chromatographic and microbiologic methods. The plasma half-lives were 7.6 and 8.3 hours, respectively, for the intravenous infusion and intramuscular injection. Plasma concentrations were equal for the 1 g intravenous and intramuscular routes by 2.5 hours. Plasma concentrations exceeded the minimal inhibitory concentrations (MICs) of most aerobic gram-positive and gram-negative organisms with the exception of Pseudomonas aeruginosa and Acinetobacter species for 24 hours. Urinary concentrations exceeded 100 micrograms/ml for 24 hours for the 1-g doses and for 12 hours for the 0.5-g dose. Urinary recovery of ceftriaxone within 24 hours was 40 percent for intravenous infusion and 33 and 34 percent for the intramuscular injection. A single 1-g dose daily will exceed the MICs of most staphylococcal and streptococcal species and Enterobacteriaceae for 12 to 24 hours.

Adult↗

PubMed1997

[Demonstration of tissue lesions after intramuscular injection by determination of creatine kinase in blood].

Local muscle tissue damage by Terramycin-LA (20 mg/kg BM) injected at the neckmuscle was tested with seven pigs prepared with veneous catheters. Four of the pigs were used as the control group and were treated with an intramuscular injection of 0.9% NaCl-solution into the opposite neckmuscle later on. The tissue damage was clinically, pathologically and enzymatically examined. A significant rise of creatinkinase (CK) in bloodplasma up to 48 hours after intramuscular injection of Terramycin-LA proves to be a good indicator of local muscle damage. Based on enzymekinetic calculations it was possible to estimate the amount of muscle laesions after intramuscular injection of Terramycin-LA up to 13 g/100 kg BM and of NaCl-solution up to 0.5 g/100 kg BM respectively. The difference is significant.

Animals↗

PubMed1951